ikenaoncology.com (IMA) Price-to-Projected Revenue Ratio
ImageneBio Inc is currently optimizing expenses and seeking strategic allies. The company's capital is based on the development of targeted cancer therapies and licenses. The company's forward P/S reflects a fundamental margin of safety, with the value holding at 0.00. Business scaling relies on partnerships with pharma behemoths that assume the manufacturing costs.
IMA (ikenaoncology.com): analytical breakdowns and indicator data
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
- financial results and valuation multiples details:
IMA - Net Financial Result|Expected Profit ImageneBio Inc|IMA - Market Cap to Earnings|Projected Price to Earnings Ikena Oncology|IMA - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple IMA|IMA - Operating income before deduction of amortization|Earnings per share for the last twelve months Ikena Oncology|IMA - Earnings per share for the last 12 months|Quarterly EPS earnings growth ikenaoncology.com|IMA - Net earnings per share growth this year|Earnings growth forecast for next year ImageneBio Inc
- total revenue and sales volume data:
Fundamental company valuation:Ikena Oncology, Inc. IMA
Forward P/S reflects the market value of an asset relative to expected revenue, discounted at the WACC rate to assess the fair value of future cash flows. By analyzing the forward P/S metric, an investor determines the extent of the premium or discount, which is critical for ImageneBio Inc. (IMA), whose capitalization is currently based on the potential of its oncotherapeutic pipeline and preparations for clinical molecule releases.
Competitor analysis
Forward P/S Multiple ARGX (argenx)|Market Cap to Expected Sales Ratio BioNTech Inc. (BNTX)|ABVX - Price-to-Projected Revenue Ratio|ADMA Corp (ADMA) - Forward Price-to-Revenue Multiple|PTGX: Forward P/S Multiple|immunovant.com (IMVT) - Forward P/S Multiple|KNSA (Kiniksa) - Forward P/S Multiple|GRFS - Projected Price to Revenue|Forward P/S Multiple ADPT|CLDX - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Aurinia Pharmaceuticals AUPH|BCRX: Market Cap to Projected Revenue|Vera Therapeutics - Forward P/S Multiple|Market Cap to Future Revenue Ratio Dianthus Therapeutics Inc|PHVS: Forward P/S Multiple|ABCL (AbCellera Corp) - Price-to-Projected Revenue Ratio|TRML (Tourmaline Bio, Inc.) - Forward P/S Multiple|precigen.com (PGEN) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Pharming Group (PHAR)|NKTR - Market Cap to Future Revenue Ratio|Upstream Bio Corp - Forward Price-to-Revenue Multiple|Forward Price to Sales ZBIO|Immunome, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio gossamerbio.com GOSS|KalVista Pharmaceuticals, Inc. (KALV) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue SEPN|PVLA (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Savara Pharma (SVRA)|Forward P/S Multiple RIGL|Market Cap to Expected Sales Ratio anaptysbio.com|Price-to-Projected Revenue Ratio Astria Therapeutics, Inc. ATXS|ENGN - Forward Price-to-Revenue Multiple|RAPT Therapeutics, Inc. - Forward P/S Multiple|JBIO - Forward P/S Multiple|Aclaris Therapeutics (ACRS) - Price-to-Projected Revenue Ratio|Future Price to Revenue KYTX (kyvernatx.com)|TLSA (Tiziana Life Sciences Ltd) - Forward P/S Multiple|CABA: Forward Price to Sales|Forward P/S Multiple VTYX|Forward P/S Multiple Theratechnologies, Inc (THTX)|Price-to-Projected Revenue Ratio Avalo Therapeutics, Inc AVTX|Forward Price to Sales ELDN|AGEN - Price-to-Projected Revenue Ratio|Climb Bio Inc. (CLYM) - Forward Price-to-Revenue Multiple|ZURA: Forward P/S Multiple|aTyr Pharmaceuticals (ATYR) - Forward P/S Multiple|Forward Price-to-Revenue Multiple ADAG|STTK: Forward Price to Sales|Forward P/S Multiple EQ|Market Cap to Expected Sales Ratio connectbiopharm.com|Price-to-Projected Revenue Ratio Immunic IMUX|ATRA - Forward Price-to-Revenue Multiple|IFRX - Price-to-Projected Revenue Ratio|x4pharma.com (XFOR) - Forward Price-to-Revenue Multiple|ACET (adicetbio.com) - Forward Price-to-Revenue Multiple|Celularity (CELU) - Forward P/S Multiple|Price-to-Projected Revenue Ratio INmune Bio Corp|Market Cap to Projected Revenue BRNS (Barinthus Biotherapeutics Corp)|Forward P/S Multiple KZR|SABS - Market Cap to Future Revenue Ratio|Forward P/S Multiple AKTX (Akari Therapeutics Plc)|Market Cap to Expected Sales Ratio Enlivex Therapeutics Ltd (ENLV)|QTTB - Price-to-Projected Revenue Ratio|GeoVax Corp (GOVX) - Forward Price-to-Revenue Multiple|EDSA: Forward P/S Multiple|ibioinc.com (IBIO) - Forward P/S Multiple|CARM (Carisma Therapeutics Inc) - Forward P/S Multiple|XTLB - Projected Price to Revenue|Forward P/S Multiple BOLT|HCWB - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Aptevo Therapeutics Inc. APVO|AIM: Market Cap to Projected Revenue|Aditxt Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio GRI Bio Inc|XRTX: Forward P/S Multiple|HIND (Vyome Therapeutics) - Price-to-Projected Revenue Ratio|REVB (Revelation Biosciences) - Forward P/S Multiple|indaptusrx.com (INDP) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Scinai Immunotherapeutics Ltd. (SCNI)|CALI - Market Cap to Future Revenue Ratio|Affimed N.V. - Forward Price-to-Revenue Multiple|Forward Price to Sales ALLK|HOOKIPA - Forward P/S Multiple|Market Cap to Expected Sales Ratio IGM Biosciences, Inc. IGMS|iTeos Therapeutics, Inc. (ITOS) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue OCEA|TCBP (TC BioPharm (Holdings) PLC) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Third Harmonic Bio Inc (THRD)
